These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31236756)

  • 1. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
    Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
    Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A; Mittra E; Dick DW; Gambhir SS
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
    Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
    Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E; Zincirkeser S; Akcan AB; Elboga U
    J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Study Comparing
    Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
    Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
    Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
    Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
    Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
    Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
    Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
    Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.